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Abstract
Background: Prediction of successful discontinuation of continuous renal replacement therapy (CRRT) might
reduce complications of over- and under-treatment. The aim of this study was to identify renal and non-renal
predictors of short-term successful discontinuation of CRRT in patients in whom CRRT was stopped because renal
recovery was expected and who were still in the Intensive Care Unit (ICU) at day 2 after stop CRRT.
Methods: Prospective multicentre observational study in 92 patients alive after discontinuation of CRRT for acute
kidney injury (AKI), still in the ICU and free from renal replacement therapy (RRT) at day 2 after discontinuation.
Successful discontinuation was defined as alive and free from RRT at day 7 after stop CRRT. Urinary neutrophil
gelatinase-associated lipocalin (NGAL) and clinical variables were collected. Logistic regression and Receiver
Operator Characteristic (ROC) curve analysis were performed to determine the best predictive and discriminative
variables.
Results: Discontinuation of CRRT was successful in 61/92 patients (66%). Patients with successful discontinuation of
CRRT had higher day 2 urine output, better renal function indicated by higher creatinine clearance (6-h) or lower
creatinine ratio (day 2/day 0), less often vasopressors, lower urinary NGAL, shorter duration of CRRT and lower
cumulative fluid balance (day 0–2). In multivariate analysis renal function determined by creatinine clearance (Odds
Ratio (OR) 1.066, 95% confidence interval (CI) 1.022–1.111, p = 0.003) or by creatinine ratio (day 2/day 0) (OR 0.149,
95% CI 0.037–0.583, p = 0.006) and non-renal sequential organ failure assessment (SOFA) score (OR 0.822, 95% CI 0.
678–0.996, p = 0.045) were independently associated with successful discontinuation of CRRT. The area under the
curve of creatinine clearance to predict successful discontinuation was 0.791, optimal cut-off of 11 ml/min (95% CI
6–16 ml/min) and of creatinine ratio 0.819 (95% CI 0.732–0.907) optimal cut-off of 1.41 (95% CI 1.27–1.59).
Conclusion: In this prospective multicentre study we found higher creatinine clearance or lower creatinine ratio as
best predictors of short-term successful discontinuation of CRRT, with a creatinine ratio of 1.41 (95% CI 1.27–1.59) as
optimal cut-off. This study provides a practical bedside tool for clinical decision making.
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Background
Acute kidney injury (AKI) is a common complication of
critical illness and patients requiring renal replacement
therapy have excess mortality even when adjusted for se-
verity of disease [1–4]. The optimal timing to start con-
tinuous renal replacement therapy (CRRT) has been
investigated in several studies. The urinary biomarker
Neutrophil gelatinase-associated lipocalin (NGAL) has
high potential as an early predictor of severe AKI [5, 6].
However, only few studies are available on the use of
biomarkers to predict successful discontinuation of
CRRT [7–9].
In daily practice, CRRT is discontinued on an individual
basis: when urinary output increases or when the CRRT
session ends and the attending physician supposes that
renal function will recover because other organ functions
improve. Previous studies found that lower age, less severe
organ failure, shorter duration of CRRT, higher creatinine
clearance or urine output during CRRT and decreasing
plasma NGAL on the first day of RIFLE-F were associated
with recovery [4, 7–15]. Clinical reasons for re-initiation
of CRRT are fluid overload, hyperkalaemia and azotaemia
[15]. However, none of these studies evaluated biomarkers
at discontinuation of CRRT.
Predicting short-term successful discontinuation in pa-
tients in whom CRRT has been stopped may prevent po-
tentially harmful complications of over- and under
treatment. We hypothesized that high urine output, high
endogenous creatinine clearance or low creatinine ratio,
low urinary NGAL, no vasopressor use and low
non-renal sequential organ failure assessment (SOFA)
score after discontinuation are associated with successful
discontinuation of CRRT. The objectives of the present
study were to identify renal and non-renal predictors for
short-term successful discontinuation.
Methods
Study design
We performed a prospective multicentre observational
study in 4 intensive care units (ICUs) in the Netherlands
(Erasmus (University) Medical Centre, Rotterdam, Ikazia
Hospital Rotterdam, Amphia Hospital Breda and Med-
ical Centre Alkmaar). Patients were included from May
2013 until September 2015. The protocol was approved
by the medical ethics committee of the Erasmus Medical
Centre and the local ethical committees. Written in-
formed consent was obtained from all participants or
their legal representative.
Patients
All patients aged 18 years or older, alive and still admitted
to the ICU at day 2 after discontinuation of CRRT were
screened for eligibility. Patients with end-stage-renal-disease
(CKD 5) with or without chronic renal replacement therapy,
and patients receiving CRRT for other reasons than acute
renal failure (e.g. liver failure, intoxications) were excluded.
Patients discharged from the ICU before day 2 were ex-
cluded from analysis, because primary study variables could
not be collected from these patients.
Sample size calculation
For evaluation of predictors of short-term successful dis-
continuation, we defined five primary study variables
(urine output, renal function determined by calculated
creatinine clearance or creatinine ratio, urinary NGAL,
vasopressor use and non-renal SOFA score) which were
hypothesized predictive and two secondary study vari-
ables (duration of CRRT and cumulative fluid balance)
which were derived from the literature. We planned to
test a total of 7 variables in multivariate regression ana-
lysis and therefore aimed to include at least 70 evaluable
patients as suggested by Altman (“no more than n/10
variables, where n is the sample size” [16]). Because of
expected exclusions caused by early discharge and miss-
ing urine samples we aimed to include 90 patients.
Study protocol and measurements
Successful discontinuation was defined as alive and free
from RRT at day 7 after discontinuation. We chose 2
days after discontinuation of CRRT as time point to pre-
dict whether discontinuation of CRRT would be success-
ful for the subsequent 5 days to include only those
patients for whom the prediction of successful discon-
tinuation has direct logistical consequences for the unit,
and to evaluate only the patients in whom CRRT was
discontinued because of expected renal recovery and not
those in whom CRRT was temporarily discontinued for
logistical reasons (such as CT scan or surgery) or switch
of dialysis modality to intermittent haemodialysis. Day 0
was defined as the first 6 a.m. after discontinuation of
CRRT. Day 7 as the day at which the outcome successful
discontinuation was determined (Fig. 1). The decision to
(re)initiate or discontinue renal replacement therapy in
the ICU was made according to the decision of the local
team. CRRT was performed according to the local
protocol of the hospital as continuous venovenous
hemofiltration (CVVH) or continuous venovenous
haemodialysis (CVVHD) and delivered dose was 20–35
ml/kg/hour. We used polyethersulfone, acrylonitrile/ so-
dium methallyl sulfonate polymer membranes with a
surface area of 1.8 m2–1.9 m2 and an in vitro cut-off
point of 30–55 kDa, depending on local availability of
materials.
Study variables
The following primary study variables were collected at
day 2: urine output, renal function determined by 6-h en-
dogenous creatinine clearance and incremental creatinine
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ratio, urinary NGAL concentration (when diuresis was
> 200ml/day) normalized to urinary creatinine concentra-
tion, vasopressor use and non-renal SOFA score. Renal
function was determined by calculation of creatinine clear-
ance according to the following formula: ((urinary creatin-
ine concentration * urine volume)/ plasma creatinine
concentration)/ 360, and calculation of the incremental
creatinine ratio between day 2 and day 0 (at discontinu-
ation) (creatinine day 2/day 0). The following secondary
study variables were collected on day 2 as well: duration of
CRRT (as found in previous studies [10, 11, 14, 15]) and
cumulative fluid balance from day 0 until day 2 (as used in
clinical practice as reason for restart).
Other measurements
The following variables were determined at start of
CRRT: demographic data, preadmission creatinine (de-
fined as creatinine 1 month prior to admission or more
without disease), preadmission estimated glomerular fil-
tration rate (eGFR) (calculated with CKD-EPI formula
[17]), previous kidney disease, reason for ICU admission
(post-operative, respiratory failure, sepsis, post cardiac
arrest, neurologic, cardiac failure), disease severity scores
(Acute Physiology And Chronic Health Evaluation
(APACHE) III, Simplified Acute Physiology Score
(SAPS) III), cause of AKI (defined as sepsis, toxic, pri-
mary renal disease, ischemic/other).
Endpoints
The primary endpoint was successful discontinuation,
defined as alive and free from any form of RRT at day 7
after stop CRRT.
Assays
For determination of NGAL, a tube collected from a 6 h
urine portion was stored in the refrigerator for a max-
imum of 72 h. As soon as possible the sample was cen-
trifuged for 10 min at 2000G at 4 °C and the supernatant
was stored at − 80 °C for determination of urinary NGAL
later. Urinary NGAL was determined by immunoassay
using the Architect ci4100 (Abbott Diagnostics, Abbott
Park, IL, US), we used the Urine NGAL Rgt 100 T
(1P37–25), NGAL Calibrator (1P37–01), NGAL Con-
trole (1P37–10) according to manufacturer’s specifica-
tions. NGAL values were normalized to creatinine
concentration and expressed as (ng/ml)/creatinine
(mmol/L).
Statistical analysis
Variables were tested for normal distribution using the
Kolmogorov-Smirnov test. Normally distributed vari-
ables are expressed as mean (standard deviation),
non-normally distributed variables as median [25th and
75th percentile], and categorical data as number and
percentage. Unpaired Student’s t-test, Mann-Whitney-U
test or Chi-square test was used, where appropriate.
Statistical significance was defined as p < 0.05.
To determine the association between the primary
study variables (urine output, endogenous creatinine
clearance, urinary NGAL, use of vasopressors and
non-renal SOFA score) and the secondary study vari-
ables (duration of CRRT and fluid balance day 0–2) with
successful discontinuation of CRRT, univariate logistic
regression analysis was performed and subsequent
multivariate analysis was performed. For all analyses,
multicollinearity was checked with a maximum variance
inflation factor (VIF) of 10.
A ROC curve was drawn for the best discriminative
variable of successful discontinuation of CRRT. The area
under the receiver operator characteristic curve (AUC)
was calculated to discriminate for successful discontinu-
ation of CRRT. The Youden index was calculated to de-
termine the optimal cut-off to discriminate for
successful discontinuation. The confidence interval for
the optimal cut-off was calculated using bootstrapping
with 1000 random samples using the bias corrected and
accelerated method.
Fig. 1 study outline
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Results
Flowchart
Of the 490 patients receiving CRRT during the study
period, 57 patients met the exclusion criteria, 155 pa-
tients died during CRRT, 13 patients were transferred
to another hospital during CRRT, 110 patients were
discharged from the ICU before the predefined sam-
pling point at day 2, 25 patients had missing primary
study variables and in 38 patients CRRT was discon-
tinued because of switch of modality to intermittent
haemodialysis. Among the 92 included patients, 61
patients (66%) experienced successful discontinuation
of CRRT at day 7, 21 patients (23%) needed
re-initiation of RRT before day 7, and 10 patients
(11%) died within 7 days after discontinuation of
CRRT (Fig. 2). Of the 173 excluded patients who
were alive and on the ICU at discontinuation of
CRRT, 105 patients (61% of excluded patients) experi-
enced successful discontinuation, 58 patients (33% of
excluded patients) needed re-initiation of RRT and 10
patients (6% of excluded patients) died within 7 days
(Fig. 2). In 38/58 patients needing restart of RRT,
CRRT was discontinued for switch to intermittent
haemodialysis.
Differences between included and excluded patients
are depicted in Table 1. Excluded patients had worse
preadmission renal function compared to included pa-
tients. Furthermore re-initiation of intermittent haemo-
dialysis was needed in 38 patients (22%) of the excluded
patients compared to 4 patients (4%) of the included
patients.
Patient characteristics according to successful or
unsuccessful discontinuation
Demographic and baseline characteristics at CRRT initi-
ation were not significantly different between patients
with successful and unsuccessful discontinuation of
CRRT (Table 2). Accordingly, events during and after
CRRT, such as new infections, the use of nephrotoxic
medication or intravenous contrast, use of diuretics and
the use of citrate anticoagulation were not significantly
different between patients with successful and unsuc-
cessful discontinuation of CRRT (Table 2).
At day 2 after stop CRRT, patients with successful dis-
continuation of CRRT had higher urine output, 2.424
(1.232) L vs. 1.640 (1.217) L (p = 0.005), higher creatinine
clearance, 29 [14, 56] ml/min vs. 7 [4, 16] ml/min
(p < 0.001), lower creatinine ratio (day 2 / day 0), 1.16
[0.91, 1.39] vs. 1.63 [1.42, 1.82] (p < 0.001), lower urinary
NGAL(ng/ml)/creatinine (mmol/L), 80 [10, 249] vs. 583
[203, 1027] (ng/ml)/ creatinine (mmol/L) (p = 0.002), less
often vasopressors 10 (16%) vs. 12 (39%) (p = 0.018) com-
pared to patients with unsuccessful discontinuation of
CRRT. Furthermore, patients with successful discontinu-
ation of CRRT had shorter duration of CRRT, 4 [3, 9] days
vs. 7 [4, 17] days (p = 0.014), and negative cumulative fluid
balance between day 0 and 2, − 1.284 (2.884) L vs. 1.250
(2.942) L (p < 0.001) (Table 3).
Association between day 2 variables and successful
discontinuation of CRRT
In univariate regression analysis we found a significant
association between successful discontinuation of CRRT
Fig. 2 flowchart of included and excluded patients
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and higher day 2 urine output (OR 1.777, 95% CI 1.168–
2.704, p = 0.007), higher creatinine clearance (OR 1.069,
95% CI 1.030–1.109, p < 0.001), lower incremental creatin-
ine ratio (day 2/ day 0) (OR 0.100, 95% CI 0.027–0.370, p
= 0.001), lower urinary NGAL (ng/ml)/creatinine (mmol/
L) (OR 0.998, 95% CI 0.997–1.000, p = 0.025), no vaso-
pressor use (OR 0.310, 95% CI 0.115–0.836, p = 0.021),
shorter CRRT duration (OR 0.926, 95% CI 0.868–
0.987, p = 0.018) and lower cumulative fluid balance
(OR 0.734, 95% CI 0.618–0.876, p = 0.001). Non-renal
SOFA score was associated with successful discon-
tinuation although non-significantly (Table 4).
Urinary NGAL was only available in 63 patients. Rea-
sons for missing values were anuria or failure to collect
or store the urine portion. The primary multivariate ana-
lysis was performed in the entire group (n = 92), because
inclusion of urinary NGAL would cause a substantial loss
of data. The analysis showed that a higher day 2 calculated
creatinine clearance (OR 1.066, 95% CI 1.022–1.111, p =
0.003), and a lower non-renal SOFA score (OR 0.822, 95%
CI 0.678–0.996, p = 0.045) were significantly associated
with successful discontinuation of CRRT, a negative fluid
balance contributed non-significantly (OR 0.848, 95% CI
0.708–1.014, p = 0.071) (Table 5).
A second multivariate analysis in the entire group (n = 92)
including incremental creatinine ratio (day 2/ day 0) instead
of creatinine clearance, showed that a lower creatinine ratio
(day 2/ day 0) (OR 0.149, 95% CI 0.038–0.583, p= 0.006)
Table 1 Baseline characteristics for included and excluded patients
Included patients n = 92 Excluded patients n = 173 P-value
Age (years) 66 [55, 74] 64 [57, 74] 0.620
Male gender, nr (%) 55 (60) 126 (73) 0.030
Weight (kg) 82 (16) 80 [71, 95] 0.693
BMI (kg/m2) 25.7 [23.5, 30.3] 27.0 [23.7, 30.9] 0.522
Previous kidney disease, nr (%) 20 (22) 57 (32) 0.056
Preadmission creatinine, μmol/L 96 [74, 127] 103 [83, 149] 0.030
Preadmission eGFR (CKD-EPI), (ml/min/1.73m2) 67.8 (26.2) 60.8 (26.7) 0.047
Cause of AKI, nr (%)
Sepsis 34 (37) 51 (30) 0.052
Toxic 4 (4) 24 (14)
Primary renal disease 2 (2) 8 (5)
Ischemic/ other 52 (57) 90 (52)
Reason for ICU admission, nr (%)
Post-operative 32 (35) 53 (31) 0.470
Respiratory failure 15 (16) 24 (14)
Sepsis 17 (19) 30 (17)
Post cardiac arrest 7 (7) 14 (8)
Cardiac failure 9 (10) 20 (12)
Other 12 (13) 32 (19)
SAPS III admission 53 (16) 54 (15) 0.313
APACHE III admission 89 (31) 81 [66, 103] 0.188
Mechanical ventilation at initiation of CRRT 69 (75) 109 (63) 0.107
Vasopressor at initiation of CRRT 74 (80) 117 (68) 0.041
Successful stop CRRT, nr (%)
Yes 60 (65) 105 (61) 0.001
No, restart of CRRT 18 (20) 20 (11)
No, restart of IHD 4 (4) 38 (22)
No, death 10 (11) 10 (6)
Mean (standard deviation) for normally distributed variables, median [25th and 75th percentile] for non-normally distributed variables, number (percentage)
when appropriate
BMI body mass index, eGFR estimated glomerular filtration rate, CKD-EPI chronic kidney disease epidemiology collaboration, AKI acute kidney injury, ICU intensive
care unit, SAPS III simplified acute physiology score, APACHE III acute physiology and chronic health evaluation score, CRRT continuous renal replacement therapy,
IHD intermittent haemodialysis
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and a lower non-renal SOFA score (OR 0.836, 95% CI
0.700–1.000, p= 0.049) were significantly associated with
successful discontinuation of CRRT, a negative fluid balance
contributed non-significantly (OR 0.830, 95% CI 0.686–
1.005, p= 0. 057) (Table 6). The Nagelkerke R2 of the latter
model was lower than that of the model including creatinine
clearance. There was no significant collinearity, the VIF
were < 3 for all combinations of variables.
A sensitivity analysis was performed in the group in
which urinary NGAL(ng/ml)/creatinine (mmol/L) was
available (n = 63). In this analysis a higher creatinine
clearance (OR 1.088, 95% CI 1.028–1.151), p = 0.004,
and lower non-renal renal SOFA (OR 0.764, 95% CI
0.604–0.765), p = 0.024, were significant predictors of
successful discontinuation. Urinary NGAL (ng/ml)/cre-
atinine (mmol/L) was removed in step 3 (Table 7).
Table 2 Demographic and baseline characteristics at start of CRRT and events during or after CRRT according to successful or
unsuccessful discontinuation
All patients n = 92 Successful stop
CRRT n = 61 (66%)
Unsuccessful stop
CRRT n = 31 (34%)
P-value
Age (years) 66 [55, 74] 62 (13) 64 (14) 0.275
Male gender, nr (%) 55 (60) 38 (62) 17 (55) 0.491
Weight (kg) 82 (16) 84 (17) 79 (15) 0.153
BMI (kg/m2) 25.7 [23.5, 30.3] 26.5 [23.9, 32.1] 25.1 [22.9, 27.7] 0.146
Previous kidney disease, nr (%) 20 (22) 10 (16) 10 (32) 0.081
Preadmission creatinine, μmol/L 96 [74, 127] 101 (39) 96 [71, 139] 0.599
Preadmission eGFR (CKD-EPI),
(ml/min/1.73m2)
67.8 (26.2) 69.5 (25.1) 64.1 (46.0) 0.375
Cause of AKI, nr (%)
Sepsis 34 (37) 19 (31) 15 (48) 0.058
Toxic 4 (4) 3 (5) 1 (3)
Primary renal disease 2 (2) 0 (0) 2 (7)
Ischemic/ other 52 (57) 39 (64) 13 (42)
Reason for ICU admission, nr (%)
Post-operative 32 (35) 20 (33) 12 (39) 0.185
Respiratory failure 15 (16) 10 (17) 5 (16)
Sepsis 17 (19) 8 (13) 9 (29)
Post cardiac arrest 7 (7) 7 (11) 0 (0)
Cardiac failure 9 (10) 7 (11) 2 (6)
Other 12 (13) 9 (15) 3 (10)
SAPS III admission 53 (16) 52 (15) 55 (18) 0.470
APACHE III admission 89 (31) 88 (29) 91 (36) 0.624
Mechanical ventilation at initiation of CRRT 69 (75) 45 (74) 24 (77) 0.702
Vasopressor at initiation of CRRT 74 (80) 49 (80) 25 (81) 0.971
Events during or after CRRT
Infection day −4 until day 0, nr (%) 21 (23) 14 (24) 7 (23) 0.936
Infection day 0 until day 7 after stop
CRRT, nr (%)
17 (19) 9 (15) 8 (26) 0.197
Citrate anticoagulation, nr (%) 74 (80) 49 (80) 25 (81) 0.971
Nephrotoxic medication or IV contrast,
day −4 until day 0, nr (%)
68 (75) 43 (71) 25 (81) 0.350
Nephrotoxic medication or IV contrast,
day 0 until day 7 after stop, nr (%)
62 (67) 43 (71) 19 (61) 0.374
Diuretics day 0 until day 2, nr (%) 73 (80) 45 (74) 28 (90) 0.064
Mean (standard deviation) for normally distributed variables, median [25th and 75th percentile] for non-normally distributed variables, number (percentage)
when appropriate
BMI body mass index, eGFR estimated glomerular filtration rate, CKD-EPI chronic kidney disease epidemiology collaboration, AKI acute kidney injury, ICU intensive
care unit, SAPS III simplified acute physiology score, APACHE III acute physiology and chronic health evaluation score, CRRT continuous renal replacement therapy
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Discrimination of renal function determined as creatinine
clearance or creatinine ratio (day 2/day 0) to predict
successful discontinuation of CRRT
The AUC of the ROC curve for creatinine clearance to
discriminate for short-term successful discontinuation of
CRRT was 0.791 (95% CI 0.697–0.885) (Fig. 3a), with an
optimal cut-off of 11 ml/min (95% CI 6–16ml/min), sen-
sitivity 0.84, specificity 0.68, positive predictive value of
84% and negative predictive value of 68%. The AUC of
the ROC curve of the final model, including creatinine
clearance, non-renal SOFA score and cumulative fluid
balance, was 0.838 (95% CI 0.757–0.919) (Fig. 3a).
The AUC of the ROC curve for creatinine ratio (day
2/day 0) to discriminate for short-term successful dis-
continuation of CRRT was 0.819 (95% CI 0.732–0.907)
(Fig. 3b), with an optimal cut-off of 1.41 (95% CI 1.27–
1.59), sensitivity 0.80, specificity 0.81, positive predictive
value 89% and negative predictive value of 68%. The
AUC of the ROC curve of the final model including cre-
atinine ratio (day 2/ day 0), non-renal SOFA score and
cumulative fluid balance is 0.840 (0.756–0.925) (Fig. 3b).
Discussion
In this prospective multicentre study in critically ill pa-
tients receiving CRRT for AKI, we found that a better
renal function determined by a higher day 2 creatinine
clearance or a lower creatinine ratio (day 2/ day 0) and a
lower non-renal SOFA score after discontinuation of
CRRT were independently associated with successful
discontinuation of CRRT at day 7. A less positive fluid
balance improved the model, but the association was not
significant. With an AUC of 0.791, the discrimination of
creatinine clearance was good, with an optimal cut off
for successful discontinuation of 11 ml/min (95% CI 6–
16ml/min), and with an AUC of 0.819, the discrimin-
ation of creatinine ratio (day 2/day 0) was also good,
Table 3 Potential predictors of successful discontinuation collected on day 2
All patients n = 92 Successful stop
CRRT n = 61 (66%)
Unsuccessful stop
CRRT n = 31 (34%)
P-value
Primary study variables
Urine output (L) 2.160 (1.276) 2.424 (1.232) 1.640 (1.217) 0.005
Creatinine clearance, ml/min 20 [7, 41] 29 [14, 56] 7 [4, 16] < 0.001
Creatinine ratio (day 2/ day 0) 1.35 [1.06, 1.63] 1.16 [0.91, 1.39] 1.63 [1.42, 1.81] < 0.001
Urinary NGAL (ng/ml)/ creatinine
(mmol/L) (n = 63)
152 [15, 601] 80 [10, 249] 583 [203, 1027] 0.002
Vasopressor use, nr (%) 22 (24) 10 (16) 12 (39) 0.018
Non-renal SOFA score 4 [3, 7] 4 [3, 5] 6 (3) 0.080
Secondary study variables
Duration of CRRT (days) 5 [3, 10] 4 [3, 9] 7 [4, 17] 0.014
Cumulative fluid balance, day 0–2 (L) −0.430 (3.129) −1.284 (2.884) 1.250 (2.942) < 0.001
Mean (standard deviation) for normally distributed variables, median [25th and 75th percentile] for non-normally distributed variables, number (percentage)
when appropriate
NGAL neutrophil gelatinase-associated lipocalin, SOFA sequential organ failure assessment, CRRT continuous renal replacement therapy
Table 4 Univariate analysis of variables associated with successful discontinuation (n = 92)
OR 95% CI P-value
Primary study variables
Urine output (L) (day 2) 1.777 1.168–2.704 0.007
Creatinine clearance, ml/min (day 2) 1.069 1.030–1.109 < 0.001
Creatinine ratio (day 0 / day2) 0.100 0.027–0.370 0.001
Urinary NGAL (ng/ml)/creatinine (mmol/L) (day 2) (n = 63) 0.998 0.997–1.000 0.025
Vasopressor use (day 2) 0.310 0.115–0.836 0.021
Non-renal SOFA score (day 2) 0.854 0.729–1.001 0.052
Secondary study variables
Duration of CRRT (days) 0.926 0.868–0.987 0.018
Cumulative fluid balance, day 0–2 (L) 0.734 0.618–0.876 0.001
OR Odds ratio; The odds ratios are per unit increase, 95% CI 95% confidence interval, NGAL neutrophil gelatinase-associated lipocalin, SOFA sequential organ
failure assessment, CRRT continuous renal replacement therapy
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with an optimal cut-off for successful discontinuation of
1.41 (95% CI 1.27–1.59). On univariate analysis, urine
output, urinary NGAL (ng/ml)/creatinine (mmol/L),
duration of CRRT and vasopressor use were significantly
associated with successful discontinuation, but these var-
iables were removed in multivariate analysis. Of interest,
in patients with successful discontinuation cumulative
fluid balance (day 0–2) was negative, while in patients
with unsuccessful discontinuation cumulative fluid bal-
ance (day 0–2) was positive, whereas the use of diuretics
was not significantly different between patients exhibit-
ing successful vs. unsuccessful discontinuation. The lat-
ter were apparently not able to remove fluid due to
insufficient renal function, persistent associated organ
failure or both.
Nowadays there are no guidelines on when CRRT in
the ICU can be discontinued. Physicians decide on indi-
vidual basis, based on bedside parameters or logistic fac-
tors, for example when the patient has to undergo a CT
scan or when the circuit has to be replaced. In the
present study, previously defined variables were pro-
spectively collected from all included patients. The find-
ing that calculated creatinine clearance from a 6-h
portion was the best predictor is important because it is
an easy and cheap marker and available within hours.
When creatinine clearance is higher than 16 ml/min, the
upper limit of the 95% confidence interval, successful
discontinuation is likely. In case of doubt, when creatin-
ine is within the 95% confidence limits, SOFA score and
fluid balance can be considered. A higher SOFA score or
a more positive fluid balance could be an argument for
restart.
The creatinine ratio (day 2/ day 0) was also predictive,
however, the multivariate model including creatinine
clearance was more sensitive. Creatinine ratio is pres-
ently used to classify the severity of AKI according to
the KDIGO guidelines during its development [18]. In
these guidelines a creatinine ratio from 1.5–1.9 times
baseline is defined as AKI stage 1. In the present study
we found that an incremental creatinine ratio (day 2/day
0) below 1.41 discriminated for short-term successful
discontinuation. Our study therefore provides practical
and plausible tools for clinical decision making.
Up to now, only retrospective studies or a post hoc
analysis evaluated the association between variables at
discontinuation of CRRT and successful discontinuation.
Urine output was the best predictor of successful discon-
tinuation of CRRT in two studies evaluating current
practice on discontinuation of CRRT [10, 11]. Only one
study also evaluated the association between creatinine
clearance and successful discontinuation of CRRT. This
study used a 2-h creatinine clearance and found an opti-
mal cut-off of 23 ml/min. However, this retrospective
study evaluated calculated creatinine clearance in the 12
h preceding discontinuation and did not evaluate the
contribution of SOFA score to the final model. Further-
more the reasons to re-initiate RRT might have been dif-
ferent [13]. We prospectively confirmed that measuring
creatinine clearance is the best predictor of short-term
successful discontinuation.
Urinary NGAL was lower in patients with successful
discontinuation, suggesting less kidney damage. How-
ever, contrary to expectation the association between
urinary NGAL and successful discontinuation was
non-significant in multivariate analysis. Urinary NGAL
is a promising early biomarker predicting AKI and need
Table 5 Primary multivariate analysis of variables associated
with successful discontinuation of CRRT (n = 92)
OR 95% CI P-value
Creatinine clearance, ml/min (day 2) 1.066 1.022–1.111 0.003
Non-renal SOFA (day 2) 0.822 0.678–0.996 0.045
Cumulative fluid balance, day 0–2 (L) 0.848 0.708–1.014 0.071
Variables included: Urine output (day 2), creatinine clearance (day 2),
vasopressor use (day 2), non-renal SOFA score (day 2), duration of CRRT (days),
cumulative fluid balance, day 0–2
Variables removed: step 2: Urine output (day 2) was lost, step 3: duration of
CRRT was lost, step 4: Vasopressor use (day 2) was lost
Nagelkerke R2 of final model 0.415
OR Odds ratio; The odds ratios are per unit increase, 95% CI 95% confidence
interval, SOFA sequential organ failure assessment
Table 6 Second multivariate analysis of variables associated
with successful discontinuation of CRRT (n = 92)
OR 95% CI P-value
Creatinine ratio (day 2 / day 0) 0.149 0.038–0.583 0.006
Non-renal SOFA (day 2) 0.836 0.700–1.000 0.049
Cumulative fluid balance, day 0–2 (L) 0.830 0.686–1.005 0.057
Variables included: Urine output (day 2), creatinine ratio (day 2 / day 0),
vasopressor use (day 2), non-renal SOFA score (day 2), duration of CRRT (days),
cumulative fluid balance, day 0–2
Variables removed: step 2: Vasopressor use (day 2) was lost, step 3: duration of
CRRT was lost, step 4: Urine output (day 2) was lost
Nagelkerke R2 of final model 0.356
OR Odds ratio; The odds ratios are per unit increase, 95% CI 95% confidence
interval, SOFA sequential organ failure assessment
Table 7 Multivariate sensitivity analysis including only the
patients with available urinary NGAL (63 patients)
OR 95% CI P-value
Creatinine clearance, ml/min (day 2) 1.088 1.028–1.151 0.004
Non-renal SOFA (day 2) 0.764 0.604–0.965 0.024
Variables included: Urine output (day 2), creatinine clearance, ml/min (day 2),
Urinary NGAL (day 2) (ng/ml)/creatinine (mmol/L), vasopressor use (day 2),
non-renal SOFA score (day 2), cumulative fluid balance day 0–2, duration of
CRRT (days)
Variables removed: step 2: Urine output (day 2) was lost, step 3: Urinary NGAL
(ng/ml)/creatinine (mmol/L) (day 2) was lost, step 4: Vasopressor use (day 2)
was lost, step 5: duration of CRRT was lost, Step 6: cumulative fluid balance
day 0–2 was lost
Nagelkerke R2 of final model (n = 63) 0.406
OR Odds ratio; The odds ratios are per unit increase, SOFA sequential organ
failure assessment
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of RRT [5, 19, 20]. When determined 24 h after AKI
diagnosis, a decline in plasma NGAL was associated
with renal recovery after 48 h [7]. Interestingly, kinetic
eGFR calculation after initial resuscitation discriminated
better for renal recovery from AKI without RRT than
urinary biomarkers NGAL or [TIMP-2]*[IGFBP7]. Cre-
atinine clearance, creatinine ratio (day 2/ day 0) and kin-
etic eGFR reflect actual renal function while NGAL and
[TIMP-2]*[IGFBP7] reflect renal damage and cell cycle
arrest respectively. Thus a marker of renal function
seems more predictive than a marker of renal damage.
In multivariate analysis non-renal SOFA score was as-
sociated with successful discontinuation of CRRT as
well, suggesting that patients with less severe illness at
discontinuation of CRRT are more likely to experience
successful discontinuation of CRRT. A high severity of
disease has been reported as being associated with
non-recovery of renal function or re-initiation of CRRT
before [12, 14]. Our study is the first to evaluate the role
of fluid balance as a marker of successful discontinu-
ation. Incorporating fluid balance in the model improved
its prediction, although not significantly.
Our study has several limitations, first despite screen-
ing a large group of patients receiving CRRT only a
small group was included in the final analysis, mainly
because of mortality during or shortly after discontinu-
ation of CRRT, and early discharge to the ward. There-
fore we compared the excluded patients who were alive
and on the ICU at discontinuation with the included pa-
tients and found that in a large group of the excluded
patients (38/173), CRRT was discontinued for switch to
intermittent haemodialysis and not because of expected
recovery of renal function. Furthermore these excluded
patients had worse preadmission renal function. This
may have caused bias, but these patients did not fulfil
the inclusion criterion of expected renal recovery. Be-
cause of our small sample size, the multivariate model
might be overfitted. However sample size calculation
was based on the suggestion of Altman to include a
minimum of 70 patients to evaluate 7 variables in multi-
variate analysis [16]. Furthermore multicollinearity be-
tween variables may have affected the results, this was
tested and appeared not to be an issue. Unfortunately
urinary NGAL concentrations were determined in only
63 patients, because urine production was less than 200
ml/day (which was deemed unreliable) or because of lo-
gistic reasons, such as failure to collect or store the urine
portion. We cannot exclude that urinary NGAL would
be predictive in a larger cohort, but the relation with
creatinine clearance and creatinine ratio (day 2/day 0)
seems stronger. Furthermore, if urine output is less than
200 ml/day, creatinine clearance is likely low as well.
Nevertheless, the group of patients with successful dis-
continuation was large enough to demonstrate that cre-
atinine clearance or creatinine ratio (day 2/ day 0) and
non-renal SOFA score were significant predictors for pa-
tients still in the ICU and these relations are clinically
plausible. A third limitation is that we do not have data
on the day CRRT is discontinued, but on day 2 after dis-
continuation. The reason that we chose day 2 was that
the population still in the ICU is of interest for the
intensivist. Our study has several strengths, to our
knowledge this is the first prospective multicentre study
evaluating predictors of successful discontinuation of
CRRT. Second, our study provides a practical tool for
the clinician to evaluate whether discontinuation of
Fig. 3 ROC curve for the prediction of successful discontinuation of CRRT. a ROC curve for creatinine clearance and final model. Creatinine
clearance (black solid line) and the final model including creatinine clearance, non-renal SOFA score and cumulative fluid balance (dotted line). b
ROC curve for creatinine ratio (day 2/day 0) and final model. Creatinine ratio (day 2/ day 0) (black solid line) and the final model including
creatinine ratio (day 2/ day 0), non-renal SOFA score and cumulative fluid balance (dotted line)
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CRRT will be successful or not, and therefore prevent
potentially harmful complications associated with over-
or under-treatment of CRRT.
Conclusions
The present prospective multicentre study found that a
calculated 6-h creatinine clearance, a creatinine ratio
(day 2/ day 0) and non-renal SOFA score at day 2 after
discontinuation independently predicted short-term suc-
cessful discontinuation of CRRT, while urinary NGAL
did not. In our cohort, a creatinine clearance of 11 ml/
min (95% CI 6–16 ml/min) and a creatinine ratio (day 2/
day 0) of 1.41 (1.27–1.59) had the optimal cut-off. The
study therefore provides a practical bedside tool: discon-
tinuation of CRRT will likely be successful if creatinine
clearance is more than 16ml/min or incremental cre-
atinine ratio (day 2/ day 0) is below 1.27, especially in
patients with lower non-renal SOFA score and when
fluid balance becomes negative.
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